APExBIO - Abiraterone|Potent CYP17 inhibitor|CAS# 154229-19-3
Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer | Oncogene
The influence of steroid metabolism on CYP17A1 inhibitor activity | Nature Reviews Urology
Molecules | Free Full-Text | Enzyme Activity of Natural Products on Cytochrome P450
Pharmaceuticals | Free Full-Text | Mechanism of the Dual Activities of Human CYP17A1 and Binding to Anti-Prostate Cancer Drug Abiraterone Revealed by a Novel V366M Mutation Causing 17,20 Lyase Deficiency
Effect of Natural Polyphenols on CYP Metabolism: Implications for Diseases | Chemical Research in Toxicology
Preclinical models of prostate cancer — modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo | Nature Reviews Urology
Resistance to second-generation androgen receptor antagonists in prostate cancer | Nature Reviews Urology
Inhibition of cytochrome P450 3A by acetoxylated analogues of resveratrol in in vitro and in silico models | Scientific Reports
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases | Nature Reviews Drug Discovery
CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents | Nature Reviews Urology
CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents | Nature Reviews Urology
CYP17 inhibition as a hormonal strategy for prostate cancer | Nature Reviews Urology
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001 | Nature
APExBIO - TOK-001|CYP17 inhibitor and androgen receptor (AR) antagonist|CAS# 851983-85-2
CYP17 inhibition as a hormonal strategy for prostate cancer | Nature Reviews Urology
Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations | Prostate Cancer and Prostatic Diseases
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer | Nature Reviews Cancer
Drug discovery in advanced prostate cancer: translating biology into therapy | Nature Reviews Drug Discovery
CYP17 inhibitors for prostate cancer therapy - ScienceDirect
Frontiers | Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
